Cancer survival – Medxy AI

Ocular Metastasis Over Four Decades: Clinical Patterns, Survival, and Therapeutic Outcomes in 569 Patients

By MedXY 10/20/2026

A 40-year retrospective study of 569 patients with ocular metastases reveals persistently poor survival, dominated by breast and lung primaries, with vision often preserved through treatment despite no significant survival improvements over time.

news Oncology Public Health

Survival of Patients Diagnosed With Cancer During the COVID-19 Pandemic

By MedXY 04/22/2026

A cohort study of over 1 million cancer patients revealed significant reductions in 1-year survival rates during 2020-2021 compared to pre-pandemic trends, with an estimated 17,390 excess cancer deaths attributable to pandemic-related care disruptions.

news Oncology Pediatrics

Does Stage Explain It All? The BENCHISTA Study Reveals Persistent Survival Gaps in Pediatric Oncology

By MedXY 02/09/2026

The BENCHISTA study analyzes survival disparities in six childhood solid tumors across 27 countries, revealing that while stage at diagnosis influences outcomes, significant international survival variations persist for Ewing sarcoma and medulloblastoma even after stage adjustment, suggesting the need for broader healthcare system improvements.

news Oncology Public Health

Pandemic Care Disruptions Linked to Significant Decline in Short-Term Cancer Survival and 17,000 Excess Deaths

By MedXY 02/09/2026

A population-based cohort study using SEER-21 data reveals that patients diagnosed with cancer during 2020 and 2021 experienced significantly lower 1-year cause-specific survival rates compared to prepandemic trends, resulting in an estimated 17,390 excess cancer-related deaths.

news Oncology Public Health

Mapping the European Cancer Landscape: A 1.7 Million Patient Study Reveals Survival Gaps and Comorbidity Patterns

By MedXY 02/07/2026

A large-scale federated study of 1.7 million European patients highlights significant variations in cancer survival and comorbidity profiles, emphasizing the role of real-world data and the OMOP-CDM framework in benchmarking oncological outcomes and identifying clinical prodromes.

Clinical Updates Diabetes & Endocrinology news Oncology

Type 2 Diabetes and Colorectal Cancer: Immune Landscape Shapes Risk and Survival Outcomes

By MedXY 09/08/2025

Type 2 diabetes increases colorectal cancer risk and worsens survival, particularly in tumors with low immune cell infiltration, highlighting the interplay between metabolic and immune factors in cancer progression and prognosis.